Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: Experiment with mice

National Medical Journal of China

Volumn 86, Issue 24, 2006, Pages 1666-1670

  Wang, Zheng ^a   Fan, Jia ^a   Zhou, Jian ^a   Wu, Zhi Quan ^a   Qiu, Shuang Jian ^a   Yu, Yao ^a   Huang, Xiao Wu ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Carcinoma; Hepatocellular; Neoplasm metastasis; Rapamycin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BASIC FIBROBLAST GROWTH FACTOR; CYCLOSPORIN A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; RAPAMYCIN; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; LUNG METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTOR 2; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33748289469     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Chinese source. 2005, 85: 1805-1808.
2. Sun FX, Tang ZY, Liu KD, et al. Establishment of a metastatic model of human hepatocellular carcinoma in nude mice via orthotopic implantation of histologically intact tissues. Int J Cancer, 1996, 66: 239-243.
3. Hale DA, Gottschalk R, Maki T, et al. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival. Transplantation, 1997, 64: 897-900.
4. Chen H, Qi S, Xu D, et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. Transplant Proc, 1998, 30: 1039-1041.
5. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet, 2001, 40: 573-585.
6. Hashemolhosseini S, Nagamine Y, Morley SJ, et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem, 1998, 273: 14424-14429.
7. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ, 2002, 9: 99-100.
8. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med, 2002, 8: 128-135.
9. Blancher C, Moore JW, Robertson N, et al. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/ Akt signaling pathway. Cancer Res, 2001, 61:7349-7355.
10. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature, 1999, 397: 530-534.
11. Ingle GR, Sievers TM, Holt CD. Sirolimus: continuing the evolution of transplant immunosuppression. Ann Pharmacother, 2000, 34: 1044-1055.